Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...

If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...

London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...

AstraZeneca (LSE:AZN) is navigating a period of robust growth and strategic challenges. Recent developments include an 18% ...

Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart ... Some other key metrics favored AZ’s medicine.

Chinese authorities have detained AstraZeneca employees amid a probe into potential data privacy breaches and unlicensed drug ...

AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...

The partners’ ADC didn’t significantly extend survival in lung cancer patients who were expected to benefit the most from treatment in a Phase 3 trial.

AstraZeneca’s Fasenra (benralizumab ... “This trial demonstrates that a biologic medicine given in a single monthly injection ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...

FluMist approved for self-administration in the US Only influenza vaccine approved for self- or caregiver-administration at home, expanding options for influenza protection FluMist ...